Healthcare utilization of people with Type 2 diabetes in Germany: an analysis based on health insurance data

2015 ◽  
Vol 32 (7) ◽  
pp. 951-957 ◽  
Author(s):  
N. Müller ◽  
T. Heller ◽  
M. H. Freitag ◽  
B. Gerste ◽  
C. M. Haupt ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Health Insurance ◽  
Healthcare Utilization ◽  
Health Insurance Data ◽  
Insurance Data

scholarly journals Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti‐hyperglycaemic medication

2020 ◽  
Vol 37 (8) ◽  
pp. 1326-1332
Author(s):  
N. Müller ◽  
T. Lehmann ◽  
A. Klöss ◽  
C. Günster ◽  
C. Kloos ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Health Insurance ◽  
Severe Hypoglycaemia ◽  
Health Insurance Data ◽  
Insurance Data

scholarly journals Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999-2004: a national health insurance data set study

2010 ◽  
Vol 27 (6) ◽  
pp. 636-643 ◽  
Author(s):  
C. H. Chang ◽  
W. Y. Shau ◽  
Y. D. Jiang ◽  
H. Y. Li ◽  
T. J. Chang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Diabetes Prevalence ◽  
Health Insurance Data ◽  
Data Set ◽  
Insurance Data

scholarly journals Health Care Costs in Patients With Type 2 Diabetes in Flanders Based on A Combination of Clinical And Health Insurance Data

2014 ◽  
Vol 17 (7) ◽  
pp. A341 ◽  
Author(s):  
I. Odnoletkova ◽  
L. Annemans ◽  
A. Ceuppens ◽  
B. Aertgeerts ◽  
D. Ramaekers
Keyword(s):  
Type 2 Diabetes ◽  
Health Care ◽  
Health Insurance ◽  
Health Care Costs ◽  
Health Insurance Data ◽  
Insurance Data ◽  
Care Costs

Increase in the incidence of severe hypoglycaemia in people with Type 2 diabetes in spite of new drugs: analysis based on health insurance data from Germany

2017 ◽  
Vol 34 (9) ◽  
pp. 1212-1218 ◽  
Author(s):  
N. Müller ◽  
T. Lehmann ◽  
B. Gerste ◽  
J.-B. Adler ◽  
C. Kloos ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Health Insurance ◽  
Severe Hypoglycaemia ◽  
New Drugs ◽  
Health Insurance Data ◽  
Drugs Analysis ◽  
Insurance Data

scholarly journals Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

2021 ◽  
Vol 9 (33) ◽  
pp. 10198-10207
Author(s):  
Hong Ki Min ◽  
Se Hee Kim ◽  
Jong Han Choi ◽  
Kyomin Choi ◽  
Hae-Rim Kim ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Health Insurance ◽  
Health Insurance Data ◽  
Insurance Data

Antidiabetic Therapy and Rate of Severe Hypoglycaemia in Patients with Type 2 Diabetes and Chronic Kidney Disease of Different Stages – A Follow-up Analysis of Health Insurance Data from Germany

2020 ◽  
Author(s):  
Martin Busch ◽  
Thomas Lehmann ◽  
Gunter Wolf ◽  
Christian Günster ◽  
Ulrich Alfons Müller ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Health Insurance ◽  
Kidney Disease ◽  
Severe Hypoglycaemia ◽  
Anatomical Therapeutic Chemical ◽  
Diabetic Patients ◽  
Health Insurance Data ◽  
Antidiabetic Treatment ◽  
Insurance Data

Abstract Background The presence of chronic kidney disease (CKD) influences the type of antiglycaemic therapy and the risk for hypoglycaemia. Methods In 2006, 2011 and 2016 health insurance data of people with diabetes type 2 were screened for CKD and the presence of severe hypoglycaemia (sHypo). The type of antihyperglycaemic therapy was recorded due to Anatomical Therapeutic Chemical (ATC) codes up to 3 months before suffering sHypo. Results The prevalence of CKD increased from 5.3% in 2006 to 7.3% in 2011 and 11.2% in 2016. Insulin-based therapies were used in 39.0, 39.1, and 37.9% of patients with, but only in 17.7, 17.4, and 18.8% of patients without CKD. Although the proportion of the CKD stages 1, 2 and 5 decreased, CKD stages 3 and 4 increased. The proportion of sHypo in CKD declined from 2006 (3.5%) to 2011 (3.0%) and 2016 (2.2%) but was still more than 10 times higher as compared to type 2 diabetic patients without CKD (0.3/0.2/0.2%) conferring a significantly higher probability of sHypo (OR 9.30, 95%CI 9.07–9.54) in CKD. The probability of sHypo was significantly lower in 2016 than in 2006 both in patients with (OR 0.58; CI 0.55–0.61) and without CKD (OR 0.70; CI 0.68–0.73). Conclusion The prevalence of CKD increased from 2006 to 2016. Patients with CKD exhibited a 9-fold increased probability of sHypo, especially in patients treated with insulin plus oral anti-diabetic drugs. However, the rate and risk for sHypo decreased over time, probably as a consequence of new antidiabetic treatment options, better awareness of sHypo, and changed therapy goals.

scholarly journals Cardiovascular comorbidities of atopic dermatitis: using National Health Insurance data in Korea

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Hye Jung Jung ◽  
Dong Heon Lee ◽  
Mi Youn Park ◽  
Jiyoung Ahn
Keyword(s):  
Myocardial Infarction ◽  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Metabolic Diseases ◽  
Peripheral Vascular ◽  
Health Insurance Data ◽  
Korean National Health Insurance ◽  
Insurance Data

Abstract Background It is well known that atopic dermatitis (AD) is associated with other allergic diseases. Recentely, links to diseases other than allergic disease have also been actively studied. Among them, the results of studies regarding AD comorbidities, especially cardiovascular disease (CVD), have varied from country to country. Objective To analyze whether the risk of CVD is different between AD patients and healthy controls using Korean National Health Insurance Data. Methods We obtained data from 2005 to 2016 from the Korean National Health Insurance Research Database. Patients with one AD code and two AD-related tests codes were selected as AD patients, and age-and sex-matched controls to the AD patients were selected from among those without AD (1:5). Each group was investigated for accompanying metabolic syndrome (which contains hypertension, type 2 diabetes, and hyperlipidemia) and CVD (angina, myocardial infarction, peripheral vascular disease, and stroke) using ICD 10 codes. Results The incidence of metabolic diseases and CVD were significantly different between the AD and control groups. Using multivariable Cox regression, differences were adjusted for sex, age, and other CVD and metabolic diseases. As a result, not only metabolic disease, but also the CVD risk of AD patients was significantly higher than that of the control group. Patients with AD had as significantly higher risk of hyperlipidemia (hazard ratio [HR] = 33.02, p < 0.001), hypertension (HR = 4.86, p < 0.001), and type 2 diabetes (HR = 2.96, p < 0.001). AD patients also had a higher risk of stroke (HR = 10.61, p < 0.001), myocardial infarction (HR = 9.43, p < 0.001), angina (HR = 5.99, p < 0.001), and peripheral vascular disease (HR = 2.46, p < 0.001). Besides hyperlipidemia, there was no difference in risk according to AD severity. Conclusion Patients with AD have a greater risk of CVD than those without AD.

Sign in / Sign up

Export Citation Format

Share Document